Table 1.
Mode of action | Class of drug | Advantages | Disadvantages |
---|---|---|---|
Inhibition of IRF5 gene expression | Small interfering RNA | Selectivity |
Off‐target effects Delivery |
Inhibition of IRF5 gene expression | CRISPR/Cas9 |
Easy design High efficiency |
Off‐target effects |
IRF5 overexpression | Adenoviral vector |
High transduction efficiency High levels of transgene expression |
Transient transfer and expression |
Disruption of IRF5–protein interactions | Peptide inhibitors | Selectivity |
Low proteolytic stability Low conformational stability |
Disruption of IRF5–DNA interactions | Decoy oligonucleotides | Selectivity | Delivery |
Inhibition of IRF5 kinases | Kinase inhibitors | Targetable by small molecule inhibitors | May interfere with other signalling pathways |